Novavax Investor Relations https://ir.novavax.com/ Novavax Announces Entering into a License Agreement with Pfizer https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer <p>Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the...</p> 01/20/2026 https://novavax.investorroom.com/2026-01-20-Novavax-Announces-Entering-into-a-License-Agreement-with-Pfizer Novavax Announces Progress on Sanofi Agreement https://novavax.investorroom.com/2025-09-30-Novavax-Announces-Progress-on-Sanofi-Agreement <p>Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant. The companies have amended their CLA to...</p> 09/30/2025 https://novavax.investorroom.com/2025-09-30-Novavax-Announces-Progress-on-Sanofi-Agreement Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP  https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP <p>Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices (ACIP) Meeting</p> 09/19/2025 https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP Novavax Statement on Publicly Available COVID-19 Vaccine Data https://novavax.investorroom.com/Novavax-Statement-on-Publicly-Available-COVID-19-Vaccine-Data <p>Novavax is a U.S.-based biotechnology company that is proud to have successfully developed a COVID-19 vaccine as part of President Trump’s Operation Warp Speed.</p> 09/03/2025 https://novavax.investorroom.com/Novavax-Statement-on-Publicly-Available-COVID-19-Vaccine-Data